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ABSTRACT
Background: The level of HBsAg in some chronic hepatitis B virus (HBV)-infected individuals 
may decline over time so that it is not detectable in serum.
Objective: To assess the efficacy of HBV vaccine in those who lost their HBsAg without sero-
converssion to anti-HBs antibody.
Patients and Methods: From April 1993 to December 2008, of 1603 chronic HBV-infected in-
dividuals, 34 (22 men and 12 women) became HBsAg-negative in follow-up visits, with no 
detectable anti-HBs antibody and HBV DNA in their sera. They received HBV vaccination at 0, 
1 and 6 months (case group). Fifty-two subjects (30 men and 22 women) who were negative 
for HBsAg, anti-HBs and anti-HBc antibody, received HBV vaccination according to the said 
schedule (control group). Anti-HBs antibody was assessed one month after the last dose of 
vaccination in the both groups. 
Results: The mean±SD age of the case and control groups was 38±12.7 and 33.4±8.6 years, re-
spectively (p=0.07). The sex distribution between these two groups were similar (p=0.652). 
The mean±SD years of follow-up for the case group was 7.6±4.5 years. Anti-HBs antibody level 
≥10 IU/L was found in 8 (24%) subjects in the case group and in 45 (87%) in the control group 
(p<0.001). The mean±SD anti-HBs antibody level in the case group was 68±32.66 and in the 
control group 344.6±38.9 IU/L (p<0.001).
Conclusions: We found that nearly 24% of chronic HBsAg-positive subjects who lost their HB-
sAg responded to HBV and the remaining cases need to be followed for occult HBV infec-
tion.
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  Implication for health policy/practice/research/medical education: 
Clinicians especially internists should pay more attention in follow-up of patients with chronic hepatitis B infection. In the management of 
these patients special attention should be considered to those who lost HBsAg during a period of time.
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Background
Approximately two billion people in the world have sero-
logical evidence of past hepatitis B virus (HBV) infection and 
more than 400 million people are chronic carriers of HBV. 
“Chronic carrier” of HBV is defined by the presence of hepa-
titis B surface antigen (HBsAg) in the serum for more than 
six months (1, 2). Years after chronic infection, in some cases 
serum HBsAg level declines below the measurable limit. Al-
though it is unusual, it occurs in less than 1% of adult patients 
per year and 0.05% to 0.8% of those with infection acquired in 
infancy or early childhood (2, 3). Detection of HBV DNA in the 
absence of a detectable HBsAg level and occasionally other 
HBV serologic markers is termed “occult hepatitis B” (OHB) 
(4). These patients not only can transmit HBV to others, but 
may progress to chronic hepatitis, cirrhosis and hepatocel-
lular carcinoma. The prevalence of OHB in hemodialysis pa-
tients in different parts of the world is reported to be 3.8% to 
27% (5-8). The prevalence and the outcome of OHB in chronic 
HBV-infected individuals has not yet been reported. On the 
other hand, those who lost HBsAg and not seroconverted to Taheri H et al. 120 Efficacy of HBV vaccine in those who lost HBsAg
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anti-HBs with no detectable HBV DNA are frequently seen in 
the clinical practice; the outcome of this group of patients is 
not clear. Objectives: This study was therefore performed to 
evaluate the efficacy of hepatitis B vaccine in subjects who 
were  chronically  infected  with  HBV  and  lost  their  HBsAg 
over time.
Patients and Methods
Selection of the case group
From  April  1993  to  December  2008,  1603  patients  with 
chronic HBV infection were followed at the Department of 
Internal Medicine and Infectious Diseases, Babol University 
of Medical Sciences, Babol, Iran. The Departments give ser-
vice to more than 1.5 million people living in Babol, Amol, 
and  Ghaemshar  located  in  northern  Iran.  Chronic  HBV-
infected patients were followed at six-month intervals for 
determination of their viral status. We provided a follow-up 
sheet for each person for recording the data during each fol-
low-up. Our follow-up protocol was testing for HBsAg, hepa-
titis B e antigen (HBeAg) if the patient was HBeAg-positive, 
antibody against HBsAg (anti-HBs), antibody against HBeAg 
(anti-HBe), serum aspartate aminotransferase (AST), alanine 
aminotransferase  (ALT),  and  α-fetoprotein.  Liver  sonogra-
phy was performed in those aged over 40 years to find out 
any evidence of hepatocellular carcinoma. The viral markers 
were tested by ELISA (HBsAg, from Bio Merieux, the Nether-
lands; anti-HBs from Radim Italy, anti-HBc, HBeAg from Dia.
Pro Diagnostic BioProbes, Italy). These tests were repeated at 
six-month intervals. Those who lost HBsAg and were not se-
roconverted to anti-HBs with undetectable serum HBV DNA 
were retested six months later. For isolation of HBV DNA from 
plasma, we used QIAamp DNA minikit (QIAGen Gmbh). All 
processes were done based on the manufacturer's instruc-
tions. For quantification of HBV DNA, we used Roter-Geen 
3000 (Corbett Research) using Artus HBV RG PCR kit (Qia-
gen, Humburg, Germany). According to the kit instructions, 
the sensitivity of the test was 3.8 IU/mL (1 IU=7 copies/mL). 
Forty-eight (2.9%) patients became HBsAg-negative. Among 
them, two developed anti-HBs antibody and 12 had 50 to 850 
copies/mL of HBV DNA—both groups were excluded from the 
study. Therefore, 34 cases (22 men, 12 women) who were HB-
sAg- and HV DNA-negative but anti-HBe- and anti-HBc-posi-
tive in two occasions six months apart, were selected as the 
case group z (Table 1). 
Selection of the control group.
In the control group, 52 healthy individuals (30 men [58%] 
and 22 [42%] women) were evaluated. Subjects in the control 
group have never been exposed to HBV (negative for HBsAg, 
anti-HBs, and anti-HBc).
Intervention
Both groups received 20 µg hepatitis B vaccine (Engerix-B, 
SmithKline Beecham) at 0, 1 and 6 months. Sera from all sub-
jects were tested for anti-HBs antibody one month after the 
last dose of the vaccine. Anti-HBs ≥10 IU/L was considered as 
protective level in both groups. The study was approved by 
the Infectious Diseases Research Center, Babol University of 
Medical Sciences. The ethical committee also approved this 
study. Informed consent was obtained from all participants.
Statistical analysis
Data were analyzed using SPSS® ver 15. Means of two con-
tinuous variables were compared using Student’s t test and 
categorical variables were compared by x² test and Fisher’s 
exact test when appropriate. A p-value <0.05 was considered 
statistically significant. 
Results
Table 1 shows the outcome of 1603 cases with chronic HBV 
infection during the follow-up period. Our analysis includ-
ed 34 cases (22 men and 12 women) who were HBsAg- and 
HBV DNA-negative but anti-HBe- and anti-HBc-positive. The 
mean±SD age of subjects in the case group was 38±12.7 years; 
it was 33.4±8.55 years in the control group (p=0.07). The sex 
distribution in these two groups were similar (p=0.652). The 
mean±SD years of follow-up in the case group was 7.65±4.5 
years. ALT and AST in all cases were within the normal range 
during the follow-up. After vaccination, a protective anti-HBs 
antibody level (≥10 IU/L) was developed in eight (24%) of sub-
jects in the case group and in 45 (87%) in the control group 
(p=0001)  (Table  2).  The  non-responders  were  re-evaluated 
with no changes in their status. The mean±SD anti-HBs anti-
Table 1. Selection of the case group
Characteristics of the 
cases
Group 1 a
NO(%)
Group 2 b
NO(%)
Total
NO(%)
n = 1523 n = 80 n = 1603
ALT ≥80 
(IU/L)
122 (8) 23 (29) 145 (9)
AST ≥80
(IU/L)
76 (4.9) 13 (16) 89 (5.6)
High levels of 
α-fetoprotein
60 (3.9) 2 (3) 62 (3.9)
Lost HBsAg 45 (2.9) 3 (4) 48 (2.9)
Serocoverted to anti-HBs 2 (0.13) 0 (0) 2 (0.12)
Detectable HBV DNA 12 (0.8) 0 (0) 12 (0.7)
Undetectable HBV DNA  31 (2) 3 (4) 34 (2.1)
Table 2. Response to hepatitis B vaccine in the two studied groups
a Group 1: HBsAg- and anti-HBe-positive cases 
b Group 2: HBsAg- and HBeAg-positive cases
Characteristics of 
the case and the 
control group
Case group
No. = 34
Control group
No. = 52
p-value
Male
No. (%)
22 (65) 30 (58) 0.652
Female
No. (%)
12 (35) 22 (42)
age
Mean ± SD
38 ± 12.7 33.4 ± 8.5 0.07
Responded to 
hepatitis B vaccine
No. (%)
8 (24) 45 (87) <0.001
anti-HBs antibody 
level
Mean ± SD
68 ± 32.66 344.6 ± 38.99 <0.001Taheri H et al. 121 Efficacy of HBV vaccine in those who lost HBsAg
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body level in the case group was 68±32.66 and in the control 
group was 344.6±38.9 IU/L (p<0.001) (Table 1).
Discussion
In this study, the protective anti-HBs level was developed in 
24% of individuals who lost HBsAg—a finding not previously 
reported. Development of anti-HBs antibody may be a clue 
showing that they have protection and are less likely prone 
to develop chronic hepatitis, cirrhosis and hepatocellular 
carcinoma (1, 2). Twenty-six individuals in the case group in 
our study with no response after hepatitis B vaccination may 
have low levels of HBsAg, have immunologic tolerance to 
hepatitis B vaccination, and have no ability to produce anti-
HBs antibody as reported previously (9). In contrast, in the 
healthy individuals in this study, the response rate was 87%, 
like what reported earlier (10, 11). The concept of low level 
HBsAg carriers has further been supported by reports of HBV 
infection following transfusion of blood from donors with 
isolated anti-HBc antibody (12). However, incidental finding 
of cases with negative HBsAg and anti-HBs antibody and pos-
itive anti-HBc antibody are frequently reported in the inter-
mediate and highly endemic regions of HBV infection (11, 13-
17). These subjects have either chronic HBV infection but had 
lost HBsAg over time or resolved HBV infection with decrease 
in anti-HBs antibody levels below 10 IU/L. With hepatitis B 
vaccination of those with isolated anti-HBc antibody, several 
studies reported significant anti-HBs levels in 91%–96% of the 
subjects (13-17). In Korea, 34 subjects with persistent isolated 
anti-HBc antibody who were HBsAg-negative received hepati-
tis B vaccination at 0, 1 and 2 months; protective level of anti-
HBs antibody was developed in 70.6% of them. As we found in 
our study, the HBV DNA was not detectable in any of subjects 
with isolated anti-HBc antibody who had not responded to 
hepatitis B vaccination (10). Lok, et al, reported no response 
rate after three doses of hepatitis B vaccine in 28% of 32 sub-
jects with isolated anti-HBc antibody (9). Lai, et al, reported 
no anti-HBs response in 22.9% of 48 cases with isolated anti-
HBc after three doses of hepatitis B vaccination (18). Kabir, 
et al, found that among 94 cases with isolated anti-HBc who 
received three doses of HBV vaccines, 19 (20.2%) were non-
responders. They found that previous history of HBsAg posi-
tivity was associated with decreased response to vaccination 
(19). The non-responders in the above studies may be due 
to the presence of low levels of HBsAg in their sera or they 
might have immunologic tolerance to HBsAg of the vaccine, 
as we noted earlier. The selection of cases in our study (prior 
positive HBsAg with loss of this marker over time) compared 
with those mentioned in the above studies which selected 
isolated anti-HBc-positive cases may explain the large num-
ber of non-responders among our cases. We think that some 
isolated anti-HBc cases with negative HBV DNA may have 
OHB. HBV DNA may be present in hepatocytes or other sites 
and  may  re-appear  later.  Investigation  of  the  presence  of 
HBV DNA in hepatocytes of these individuals may be helpful 
and gives a potential answer to this question. Unfortunately, 
due to ethical considerations, we did not perform liver bi-
opsy in these cases. At present, an OHB is defined as “isolated 
anti-HBc cases with detectable HBV DNA measured by PCR” 
(2). In this study, we found that nearly 77% of those who lost 
HBsAg during follow-up and were negative for HBV DNA may 
still have OHB. The weakness of this study was the relatively 
small number of patients studied and lack of liver biopsy for 
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detection of HBV DNA in hepatocytes. Another weakness of 
this study may be related to spontaneous seroconversion in 
the case group with no relation to vaccination. Other studies 
with large number of cases with or without vaccination are 
necessary to confirm our findings. The results of this study 
emphasize the hypothesis that chronic HBsAg-positive cases 
who lost their HBsAg and are negative for HBV DNA in their 
sera may still have OHB.
In summary, the results showed that nearly 24% of chronic 
HBsAg-positive cases who lost their HBsAg and are negative 
for HBV DNA responded to hepatitis B vaccination; the re-
maining people must be followed for OHB. 
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